POMONA, CA / ACCESSWIRE / December 5, 2016 / Leaders of the global innovation business and defense organizations and related industries met in Austin to accelerate technology solutions in all areas of defense, including energy, cyber, medical, materials and systems. NeurAegis was invited to present its technologies directed at diagnosing and treating various forms of acute neurodegeneration, including traumatic brain injury (TBI). NeurAgis is developing "Neuritus" and "NeuroP13BP" for the treatment and diagnosis of TBI and other neurodegenerative conditions.
To further its mission, NeurAegis has started the formation of a Board of Scientific Advisors (SAB) with the appointment of several distinguished academic and pharmaceutical scientists.
• Philippe Bey, PhD
Dr. Bey has 45 years of experience in the biotechnology and pharmaceutical industry where he has participated in and led teams responsible for over 30 Investigational New Drug applications (INDs) in many therapeutic areas, including oncology, respiratory diseases, infectious diseases, inflammation, metabolic and central nervous system diseases. Dr. Bey served until October 2016 as Senior Vice President of R&D at Thrasos Therapeutics. Prior to joining Thrasos, Dr. Bey was the Chief Scientific Officer and Senior Vice President of R&D at ArQule. He also previously served as U.S. Senior Vice President of R&D at Hoechst Marion Roussel (HMR), now Sanofi.
• Michael Palfreyman, PhD
Michael is a seasoned leader in the biotechnology and pharmaceutical industries with over 40 years' experience in leadership positions He currently serves as Director of Oculogics, Inc and is a Member of the Patent Review Board, Forsyth Dental Institute. In addition to these positions, he is the Head of R&D Diligence at Torrey Pines Investment and Senior R&D Diligence at ChemRar; Chief Scientific Officer at Amorsa Therapeutics, Inc., and the Chairman of the SAB and SVP Drug Development at Aminex Therapeutics, Inc. He also serves as Scientific Advisor for Avineuro, Inc., NeuroNascent, Inc., and Jasco Pharmaceuticals, Inc. Prior to entering the biotechnology industry in 1994 he was VP Research (North America) at the Marion Merrell Dow Research Institute.
• Serge Bischoff, PhD
Dr. Serge Bischoff spent over 43 years in medical and pharmaceutical research in neurosciences. He spent most of his professional life in the large pharma industry (Synthélabo-Sanofi, Ciba-Geigy, Novartis), where he was Head of various research programs for psychiatric, neurological and neurodegenerative diseases. Author of several patents and over a hundred scientific publications and analysis articles, he is laureate of numerous awards including the Young Psychiatry Scientist Award by the Swiss Society of Psychiatry, the Leading Scientist Award at Novartis, the French National Contest of Creation of Innovative Enterprises, and very recently the World Contest of Innovation and the Valori Prize of the French Academy of Sciences.
• Gary Lynch, PhD
Dr. Gary Lynch received his PhD at Princeton University and started his academic career at UC Irvine, where he contributed to making the Psychobiology Dept a world leader in neurosciences. For almost 50 years, his work has contributed to our understanding of the mechanisms of learning and memory, and more generally on how the brain processes information. He has published over 600 publications in top journals, has been invited to numerous Symposia and meetings all over the world, and is the inventor on numerous patents. He was the co-founder of several companies, including Synaptics, Inc., Cortex Pharmaceuticals, Thorus, Inc, and Tensor, Inc. His vast knowledge in neurosciences and his experience in translating basic findings into therapeutic applications make him a terrific asset for NeurAegis.
Contact information:
Michel Baudry, CEO, NeurAegis:
[email protected]
909.469.8271
SOURCE: NeurAegis, Inc.